期刊文献+

利伐沙班与低分子肝素预防腰椎手术后下肢深静脉血栓的疗效对比 被引量:10

Compare prophylactic effects of rivaroxaban with low molecular weight heparin on deep vein thrombosis after lumbar surgery
原文传递
导出
摘要 目的比较利伐沙班与低分子肝素预防腰椎手术后下肢深静脉血栓(DVT)的疗效及安全性。方法择期腰椎手术的DVT高危患者142例,随机分为两组。利伐沙班组术后6 h开始口服利伐沙班10 mg,qd;低分子肝素组术后12 h皮下注射低分子肝素5 000 IU,qd;均于患者下床行走后停药。记录术后48 h引流量,手术前及术后7 d检测血D-二聚体水平、凝血酶原时间和活化部分凝血活酶时间。术后7 d行双下肢血管超声检查,观察下肢DVT形成情况。结果两组均无大的下肢DVT形成及肺栓塞发生。利伐沙班组术后48 h引流量(174.3±26.1)mL,低分子肝素组为(167.4±24.2)mL,组间无显著差异(P>0.05)。术后7 d,利伐沙班组发生肌间静脉血栓8例,低分子肝素组9例,组间无显著差异(P>0.05)。两组D-二聚体水平、凝血酶原时间和活化部分凝血活酶时间差异均无显著意义(P>0.05),均无消化道黏膜出血、硬膜外血肿及切口血肿发生。结论利伐沙班可以有效预防腰椎手术后下肢DVT的发生,疗效与低分子肝素相当且安全。 AIM To compare the the efficacy and safety of rivaroxaban with low molecular weight heparin (LMWH) in preventing deep venous thrombosis (DVT) after lumbar surgery. METHODS One hundred and forty- two DVT high- risk patients who had undergone lumbar elective surgery were randomly divided into two groups. The rivaroxaban group was given rivaroxaban 10 mg 6 hours after surgery, po, qd, till out of bed to walk. The LMWH group was given LMWH subcutaneously 5 000 IU 12 h after surgery, qd, till out of bed to walk. Postoperative drainage, the levels of D- dimer, prothrombin time (PT) and activated partial thromboplastin time (APTr) were detected. The formation of DVT was observed 7 d postoperatively by checking the lower extremity vascular ultrasound. RESULTS There were no serious DVT of lower extremity and pulmonary embolism in both groups. The drainage of 48 hours postoperatively in the rivaroxaban group and LMWH group showed no significant difference ((174.3 +- 26.1) mL vs. (167.4 + 24.2) mL, P 〉 0.05). Eight patients occurred myenteric vein thrombosis in rivaroxaban group and nine patients in the LMWH group (P 〉 0.05). There were no significant difference in levels of D-dimer, PT and APTY between two groups (P 〉 0.05). No digestive Rivaroxaban LMWH. tract bleeding, is effective in epidural hematoma and wound hematoma occurred in both groups. CONCLUSION preventing DVT of the lumbar surgery, and its efficacy and safety is similar to the
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2014年第3期211-214,共4页 Chinese Journal of New Drugs and Clinical Remedies
基金 烟台市科技发展计划项目(2010149-8)
关键词 利伐沙班 肝素 低分子量 静脉血栓形成 腰椎 rivaroxaban heparin, low-molecular-weight venous thrombosis lumbar vertebrae
  • 相关文献

参考文献13

  • 1WU O, CLARK P, LOWE GD, et al. Thrombophilia and venous thromboembolism after total hip or knee replacement surgery: a systematic review[J]. J Thromb Haemost, 2005, 3(4): 811-813.
  • 2PLATZER P, THALHAMMER G, JAINDL M, et al. Thrombo- embolie complications after spinal surgery in trauma patients[J]. Acta Orthop, 2006, 77(5): 755-760.
  • 3TAKAHASHI H, YOKOYAMA Y, IIDA Y, et ol. Incidence of venous thromboembolism after spine sugery [J]. J Orthop Sci, 2012, 17(2): 114-117.
  • 4SMITH JS, FU KM, POLLY DW Jr, et al. Complication rates of three common spine procedures and rates of thromboembolism following spine surgury based on 108, 419 procedures: a report from the Scoliosis Research Society Morbidity and Motality Committee[J]. Spine, 2010, 35(24): 2140-2149.
  • 5NICOL M, SUN Y, CRAIG N, et 01. Incidence of thrombo- embolic complications in lumbar spine surgery in 1111 patients [J]. Eur Spine J, 2009, 18(10) : 1548-1552.
  • 6王炜,翁习生,林进,金今,钱文伟,邱贵兴.单侧全膝关节置换术后依诺肝素与利伐沙班抗凝效果的随机对照研究[J].中国骨与关节外科,2012,5(3):198-202. 被引量:15
  • 7MILLS RM, BERKOWITZ RD, DAMARAJU CV, et al. Initia- tion of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study[J]. Thromb Res, 2012, 130(5): 709-715.
  • 8黄健斌,曾采采,丁悦,曾展鹏,马若凡,李卫平.利伐沙班与低分子肝素预防髋关节置换术后深静脉血栓形成的疗效对比[J].中国新药与临床杂志,2011,30(4):255-259. 被引量:25
  • 9GERLACH R, RAABE A, BECK J, et al. Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery[J]. Eur Spine J, 2004, 13(1 ) : 9-13.
  • 10CHENG JS, ARNOLD PM, ANDERSON PA, et al. Anticoagula- tion risk in spine surgery[J]. Spine, 2010, 35(9 Suppl) : S117- S124.

二级参考文献38

  • 1李军,朱天岳,马忠泰,柴卫兵,卢宏章,刘震宁.低分子肝素预防髋关节置换术后深静脉血栓的安全性[J].中国矫形外科杂志,2004,12(16):1223-1225. 被引量:43
  • 2邱贵兴,戴尅戎,杨庆铭,裴福兴,陈百成,曾炳芳,陈安民,王坤正,王继芳,余楠生,周乙雄,孙天胜,刘强,胡永成.预防骨科大手术后深静脉血栓形成的专家建议[J].中国临床医生杂志,2006,34(1):27-28. 被引量:55
  • 3徐西奎,程雷,聂林,汤继文.全膝关节置换术后下肢深静脉血栓形成的防治[J].中国骨与关节损伤杂志,2006,21(11):915-917. 被引量:14
  • 4邱贵兴,杨庆铭,余楠生,翁习生,王凯,李晓林.低分子肝素预防髋、膝关节手术后下肢深静脉血栓形成的多中心研究[J].中华骨科杂志,2006,26(12):819-822. 被引量:426
  • 5GEERTS WH, HEIT JA, CLAGETT GP, et al. Prevention of venous thromboembolism[J]. Chest, 2001, 119(1 Suppl): 132S-175S.
  • 6RATHBUN S. Cardiology patient pages. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism[J]. Circulation, 2009, 119 ( 15 ) : e480-e482.
  • 7SNOW V, QASEEM A, BARRY P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians[J]. Ann Intern Med, 2007, 146(3): 204- 210.
  • 8SEGAL JB, STREIFF MB, HOFMANN LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline[J]. Ann Intern Med, 2007, 146(3): 211-222.
  • 9SCHULMAN S, BEYTH RJ, KEARON C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)[J]. Chest, 2008, 133(6 Suppl) : 257S-298S.
  • 10GARCIA D, LIBBY E, CROWTHER MA. The new oral anticoagulants[J]. Blood, 2010, 115 (1) : 15-20.

共引文献48

同被引文献92

  • 1宋学坤,杨松涛.用低分子肝素联合丹红注射液治疗肺心病呼吸衰竭的疗效观察[J].求医问药(下半月),2013(7):78-79. 被引量:4
  • 2Xi Yu,Yi Tian,Ka Wang,Ying-Lin Wang,Guo-Yi Lv,Guo-Gang Tian.Effect of ulinastatin combined rivaroxaban on deep vein thrombosis in major orthopedic surgery[J].Asian Pacific Journal of Tropical Medicine,2014,7(11):918-921. 被引量:17
  • 3邱贵兴,戴尅戎,杨庆铭,裴福兴,陈百成,曾炳芳,陈安民,王坤正,王继芳,余楠生,周乙雄,孙天胜,刘强,胡永成.预防骨科大手术后深静脉血栓形成的专家建议[J].中国临床医生杂志,2006,34(1):27-28. 被引量:55
  • 4BERRY K, LERRIGO R, LIOU IW, et al. Association between transjugular intrahepatic portosystemic shunt and survival in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2016, 14 (1): 118-123.
  • 5ROSSLE M, BAUSCH B, KLINGER C. Therapy algorithm for portal vein thrombosis in liver cirrhosis: the internist's point of view[J]. Viszeralmedizin, 2014, 30(6): 401-408.
  • 6RAJA K, JACOB M, ASTHANA S, et al. Portal vein thrombosis in cirrhosis[J]. J Clin Exp Hepatol, 2014, 4(4) : 320-331.
  • 7SENZOLO M, SARTORI TM, ROSSETTO V, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosy- stemic shunt for the management of portal vein thrombosis in cirrhosis[J]. Liver Int, 2012, 32(6) : 919-927.
  • 8AMITRANO L, GUARDASCIONE MA, MENCHISE A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis[J]. J Clin Gastroenterol, 2010, 44(6): 448-451.
  • 9TUMMALA R, KAVTARADZE A, GUPTA A, et al. Specific antidotes against direct oral anticoagulants: a comprehensive review of clinical trials data[J]. Int J Cardiol, 2016, 214: 292- 298.
  • 10TURPIE AG, LASSEN MR, DAVIDSON BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthro- plasty (RECORD4): a randomised trial[J]. Lancet, 2009, 373 (9676) : 1673-1680.

引证文献10

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部